Orforglipron posts consistent weight loss across menopause stages
New post-hoc analyses presented at the European Association for the Study of Diabetes meeting add another layer to the case for orforglipron, the once-daily oral GLP-1 receptor agonist marketed as Foundayo. Across phase 3 trials, women lost substantial weight whether they were premenopausal, perimenopausal, or postmenopausal, a finding that matters because menopause often changes body composition, central fat distribution, and the day-to-day difficulty of losing weight.
The analysis drew on participants from ATTAIN-1 and ATTAIN-2. ATTAIN-1 enrolled adults with obesity or overweight and weight-related comorbidities, while ATTAIN-2 enrolled people with overweight or obesity and type 2 diabetes. Investigators then grouped women by menopausal status and reviewed outcomes already generated in those studies. This was not a trial built from the outset to test menopause as a modifier of response, so the signal is informative rather than definitive.
In ATTAIN-1, the 36 mg dose of orforglipron was linked with average weight reductions of 12.8% in premenopausal women, 14.4% in perimenopausal women, and 14.1% in postmenopausal women. In ATTAIN-2, the corresponding reductions were 11.3%, 8.9%, and 13.6%. Across both studies, waist circumference fell by as much as 12.5 cm. Up to 83% of women taking the medication reached at least 5% weight loss, compared with 30% on placebo.
That pattern matters at the bedside. Abdominal adiposity is more than a cosmetic measure; it tracks with visceral fat burden, insulin resistance, and cardiometabolic risk. A shrinking waistline often signals a biologically meaningful shift in energy balance and fat partitioning, not just a change on the scale.
Weight reduction remained broad despite hormonal transition
Menopausal transition can complicate obesity treatment. Estrogen decline tends to favor central fat gain and can alter appetite regulation, sleep, and insulin sensitivity. Those changes often make weight management feel harder for women entering and leaving menopause, even when dietary habits remain stable.
The current analysis suggests the drug’s appetite-suppressing and weight-lowering effects are not blunted by that hormonal transition. The similarity across menopausal groups is clinically useful because it suggests the GLP-1 pathway remains pharmacologically active even as reproductive hormones fluctuate. In practical terms, that means clinicians do not need to assume menopause itself predicts treatment failure with this agent.
Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, California, said the findings show that the medication helps with weight loss regardless of menopausal stage. He also pointed to the significance of the roughly 14% weight loss seen in some groups and noted that longer-term outcomes still need study.
The waist circumference data reinforce the point. Central obesity is closely tied to cardiometabolic disease risk, and reduction in abdominal girth often reflects lower intra-abdominal fat, which is the depot most strongly associated with diabetes and cardiovascular disease.
Indirect comparison favors orforglipron over oral semaglutide
A separate analysis at EASD compared orforglipron with oral semaglutide in adults with type 2 diabetes. This was not a direct head-to-head randomized trial. Instead, investigators used data from ACHIEVE-3 for orforglipron and PIONEER PLUS for oral semaglutide, then applied an indirect comparison framework.
Across that analysis, 17.2 mg of orforglipron was associated with 1.5 percentage points greater weight loss than 25 mg of oral semaglutide. The same analysis also suggested a 0.3 percentage-point greater reduction in HbA1c, the standard measure of average blood glucose. Lilly reported that alternative statistical methods yielded estimates ranging from 1.5% to 2.4% greater weight loss and 0.3% to 0.6% greater HbA1c reduction.
Indirect comparisons can be useful when no direct trial exists, but they carry obvious limitations. Trial populations, background treatments, adherence, inclusion criteria, and follow-up conditions can differ in ways that distort apparent treatment effects. The result is hypothesis-generating, not practice-changing on its own.
Even so, the comparison sits alongside a more concrete result from the head-to-head ACHIEVE-3 trial. There, 17.2 mg of orforglipron produced mean body weight loss of 9.2% at 52 weeks, compared with 5.3% for 14 mg of oral semaglutide. HbA1c fell by 2.2% and 1.4%, respectively. Those figures suggest a stronger glucose and weight response with orforglipron in that study setting.
Oral GLP-1 therapy continues to compete with injectables
The larger story here is not a single data point but the growing effort to build oral alternatives to injectable GLP-1 therapy. Oral dosing can ease the burden of treatment for patients who prefer pills over injections, yet oral delivery comes with its own constraints. Oral semaglutide requires fasting and water restrictions, while orforglipron does not share those administration requirements, making adherence simpler in everyday practice.
That convenience may matter as much as pharmacology. A drug can be highly effective in a trial and still fail in the real world if its dosing rules are too cumbersome for routine life. Once-daily oral administration without fasting restrictions could make sustained use more realistic for patients balancing work, meals, travel, and multiple medications.
The menopause analysis and the semaglutide comparison come from conference presentations rather than peer-reviewed publication, so they remain preliminary. Still, the findings point in the same direction: orforglipron appears capable of producing clinically meaningful weight loss across different female menopausal stages, and it may offer stronger glycemic and weight effects than oral semaglutide in adults with type 2 diabetes.
The unresolved questions are more specific than broad enthusiasm. Long-term durability, safety over extended use, and direct randomized comparisons against the same dose ranges remain necessary before clinicians can define where this oral GLP-1 fits among existing obesity and diabetes therapies.